vs

Side-by-side financial comparison of LCNB CORP (LCNB) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $12.5M, roughly 1.9× Avidity Biosciences, Inc.). LCNB CORP runs the higher net margin — 23.7% vs -1398.3%, a 1422.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 5.1%). LCNB CORP produced more free cash flow last quarter ($33.4M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 15.7%).

LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

LCNB vs RNA — Head-to-Head

Bigger by revenue
LCNB
LCNB
1.9× larger
LCNB
$23.9M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+428.9% gap
RNA
434.0%
5.1%
LCNB
Higher net margin
LCNB
LCNB
1422.0% more per $
LCNB
23.7%
-1398.3%
RNA
More free cash flow
LCNB
LCNB
$190.3M more FCF
LCNB
$33.4M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
15.7%
LCNB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
LCNB
LCNB
RNA
RNA
Revenue
$23.9M
$12.5M
Net Profit
$5.7M
$-174.4M
Gross Margin
Operating Margin
29.2%
-1513.5%
Net Margin
23.7%
-1398.3%
Revenue YoY
5.1%
434.0%
Net Profit YoY
-7.6%
-117.0%
EPS (diluted)
$0.40
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LCNB
LCNB
RNA
RNA
Q4 25
$23.9M
Q3 25
$23.8M
$12.5M
Q2 25
$22.8M
$3.8M
Q1 25
$21.5M
$1.6M
Q4 24
$22.7M
$3.0M
Q3 24
$21.4M
$2.3M
Q2 24
$19.3M
$2.0M
Q1 24
$17.8M
$3.5M
Net Profit
LCNB
LCNB
RNA
RNA
Q4 25
$5.7M
Q3 25
$6.9M
$-174.4M
Q2 25
$5.9M
$-157.3M
Q1 25
$4.6M
$-115.8M
Q4 24
$6.1M
$-102.3M
Q3 24
$4.5M
$-80.4M
Q2 24
$925.0K
$-70.8M
Q1 24
$1.9M
$-68.9M
Operating Margin
LCNB
LCNB
RNA
RNA
Q4 25
29.2%
Q3 25
35.6%
-1513.5%
Q2 25
31.6%
-4448.7%
Q1 25
25.6%
-8360.9%
Q4 24
32.9%
-4069.6%
Q3 24
24.9%
-4200.9%
Q2 24
4.9%
-4040.4%
Q1 24
12.5%
-2178.6%
Net Margin
LCNB
LCNB
RNA
RNA
Q4 25
23.7%
Q3 25
29.1%
-1398.3%
Q2 25
26.0%
-4089.3%
Q1 25
21.4%
-7360.0%
Q4 24
27.0%
-3439.5%
Q3 24
21.2%
-3441.7%
Q2 24
4.8%
-3461.8%
Q1 24
10.7%
-1943.4%
EPS (diluted)
LCNB
LCNB
RNA
RNA
Q4 25
$0.40
Q3 25
$0.49
$-1.27
Q2 25
$0.41
$-1.21
Q1 25
$0.33
$-0.90
Q4 24
$0.44
$-0.80
Q3 24
$0.31
$-0.65
Q2 24
$0.07
$-0.65
Q1 24
$0.15
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LCNB
LCNB
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$21.6M
$350.2M
Total DebtLower is stronger
$104.4M
Stockholders' EquityBook value
$273.9M
$1.9B
Total Assets
$2.2B
$2.1B
Debt / EquityLower = less leverage
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LCNB
LCNB
RNA
RNA
Q4 25
$21.6M
Q3 25
$35.9M
$350.2M
Q2 25
$49.8M
$243.9M
Q1 25
$37.7M
$254.2M
Q4 24
$35.7M
$219.9M
Q3 24
$39.4M
$370.2M
Q2 24
$34.9M
$575.8M
Q1 24
$33.0M
$471.4M
Total Debt
LCNB
LCNB
RNA
RNA
Q4 25
$104.4M
Q3 25
$104.7M
Q2 25
$105.0M
Q1 25
$104.6M
Q4 24
$155.2M
Q3 24
$155.7M
Q2 24
$162.2M
Q1 24
$162.6M
Stockholders' Equity
LCNB
LCNB
RNA
RNA
Q4 25
$273.9M
Q3 25
$269.9M
$1.9B
Q2 25
$263.5M
$1.2B
Q1 25
$258.7M
$1.3B
Q4 24
$253.0M
$1.4B
Q3 24
$253.2M
$1.5B
Q2 24
$245.2M
$1.2B
Q1 24
$233.7M
$830.9M
Total Assets
LCNB
LCNB
RNA
RNA
Q4 25
$2.2B
Q3 25
$2.2B
$2.1B
Q2 25
$2.3B
$1.4B
Q1 25
$2.3B
$1.5B
Q4 24
$2.3B
$1.6B
Q3 24
$2.3B
$1.6B
Q2 24
$2.4B
$1.3B
Q1 24
$2.3B
$951.5M
Debt / Equity
LCNB
LCNB
RNA
RNA
Q4 25
0.38×
Q3 25
0.39×
Q2 25
0.40×
Q1 25
0.40×
Q4 24
0.61×
Q3 24
0.61×
Q2 24
0.66×
Q1 24
0.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LCNB
LCNB
RNA
RNA
Operating Cash FlowLast quarter
$34.4M
$-156.2M
Free Cash FlowOCF − Capex
$33.4M
$-156.9M
FCF MarginFCF / Revenue
140.2%
-1257.6%
Capex IntensityCapex / Revenue
4.0%
5.7%
Cash ConversionOCF / Net Profit
6.08×
TTM Free Cash FlowTrailing 4 quarters
$54.5M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LCNB
LCNB
RNA
RNA
Q4 25
$34.4M
Q3 25
$14.0M
$-156.2M
Q2 25
$5.5M
$-199.7M
Q1 25
$2.2M
$-124.8M
Q4 24
$93.2M
$-99.9M
Q3 24
$11.9M
$-65.6M
Q2 24
$54.9M
$-65.0M
Q1 24
$-11.9M
$-70.4M
Free Cash Flow
LCNB
LCNB
RNA
RNA
Q4 25
$33.4M
Q3 25
$13.7M
$-156.9M
Q2 25
$5.2M
$-203.0M
Q1 25
$2.1M
$-128.6M
Q4 24
$89.4M
$-103.8M
Q3 24
$10.5M
$-67.3M
Q2 24
$53.8M
$-65.5M
Q1 24
$-12.8M
$-71.3M
FCF Margin
LCNB
LCNB
RNA
RNA
Q4 25
140.2%
Q3 25
57.4%
-1257.6%
Q2 25
23.0%
-5277.1%
Q1 25
10.0%
-8174.3%
Q4 24
394.0%
-3491.0%
Q3 24
49.0%
-2881.8%
Q2 24
278.6%
-3204.6%
Q1 24
-71.8%
-2012.3%
Capex Intensity
LCNB
LCNB
RNA
RNA
Q4 25
4.0%
Q3 25
1.3%
5.7%
Q2 25
1.0%
86.9%
Q1 25
0.3%
238.6%
Q4 24
16.7%
131.7%
Q3 24
6.7%
72.9%
Q2 24
5.9%
26.0%
Q1 24
4.8%
25.8%
Cash Conversion
LCNB
LCNB
RNA
RNA
Q4 25
6.08×
Q3 25
2.02×
Q2 25
0.92×
Q1 25
0.48×
Q4 24
15.23×
Q3 24
2.63×
Q2 24
59.35×
Q1 24
-6.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons